Authorised Therapeutic use (Phase IV) Chronic Kidney disease

CANagliflozin In DIAlysis Patients

EU CTIS ID: 2025-522742-46-00

What this study is testing

The main objective of this exploratory study is to investigate specific tissue distribution of SGLT2 inhibitors in patients on dialysis with-and without residual diuresis and visualize this by the use of 18F- canagliflozin.

  • Therapeutic use (Phase IV)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • 1) Dialysis for more than 3 months both HD and PD (5 also with residual diuresis) 2) Age ≥18 years of age 3) Willing to sign informed consent

You likely can't join if

  • 1) Mentally incapacitated subjects (i.e. not able to sign informed consent) 2) Subjects who participated in a trial with exposure to radiation before, are only allowed to participate if the total cumulative radiation burden in their life does not exceed 1 mSv per year, counting from the age of 18 years. 3) Pregnant women and women of child-bearing potential who are not using reliable contraception 4) Subjects on diuretics are allowed to participate but the dose should be stable for at least 4 weeks prior to screening 5) Subjects already on a SGLT2 inhibitor are allowed to participate, but the drug should be interrupted 1 week prior to the first study day till the end of the second study day 6) History of hypersensitivity to canagliflozin or another SGLT2 inhibitor 7) Severe claustrophobia 8) History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening. 9) Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following: Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months Pancreatic injury or pancreatitis within the last six months Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3x ULN at inclusion visit, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt 10) Established peripheral arterial disease 11) Active cardiovascular disease: myocardial infarction, angina pectoris, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, stroke, or heart failure (NYHA I-IV) admission < 3 months before inclusion 12) People using digoxin 13) Patients with an active malignancy

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.